LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China
Everest can pursue approval and commercialization of the eye drop in Greater China, while LENZ may receive up to $85 million in milestones and royalties.
9 Articles
9 Articles
LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize ...
SAN DIEGO, June 07, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ, “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmic solution) 1.44%, the first and only aceclidine-based eye drop for the treatment…
LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100)
SAN DIEGO, June 07, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ, "LENZ" or the "Company")), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmic solution) 1.44%, the first and only aceclidine-based eye drop for the treatment of presbyopia, today announced that Everest Medicines (HKEX1952, or "Everest"), has entered into an Asset Purchase Agreement with Corxel Pharmaceuticals ("CORXEL") to ac…
Everest Medicines Enters into Asset Purchase Agreement with Corxel Pharmaceuticals to Develop and Commercialize LNZ100 in Greater China, Strengthen Presence in Ophthalmology
HONG KONG, Jun 8, 2026 - (ACN Newswire) - Everest Medicines (HKEX 1952.HK) announced that it has entered into an Asset Purchase Agreement with Corxel Pharmaceuticals ("CORXEL"). Under the agreement, Everest has acquired the rights to develop, manufacture, and commercialize LNZ100 (1.44% aceclidine, U.S. brand name VIZZ) in Greater China, including Chinese mainland, Hong Kong SAR, Macao SAR, and Taiwan region. Everest will pay an upfront payment …
Everest Medicines Acquires Greater China Rights to Lenz Therapeutics’ Presbyopia Eye Drop Vizz
Key Takeaways Everest Medicines acquired Greater China rights to Lenz Therapeutics’ presbyopia treatment Vizz (LNZ100) from Corxel Pharmaceuticals LNZ100 is currently under regulatory review in China following NDA submission in September 2025, with approval anticipated in the first quarter of 2027 Lenz Therapeutics and Everest Medicines have expanded their partnership around presbyopia treatment Vizz (aceclidine ophthalmic solution) 1.44%, wit…
Coverage Details
Bias Distribution
- 67% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
